Image

Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients

Research Study on Treatment for Metastatic Pancreatic Cancer After First-Line Chemotherapy

Recruiting
18-75 years
All
Phase 2
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study investigates metastatic pancreatic cancer. The purpose of this study is to evaluate a combination treatment for patients whose cancer has progressed after initial chemotherapy.

The study focuses on evaluating the safety and effectiveness of combining chemotherapy with a PD-L1 inhibitor and a multi-target anti-angiogenic small molecule, with or without SBRT.

  • Who can participate: Adults aged 18 to 75 years with advanced metastatic pancreatic cancer who have not received second-line treatment can participate. Participants must have measurable lesions and meet specific health criteria.
  • Study details: Participants will receive a combination of chemotherapy drugs with a PD-L1 inhibitor and a multi-target anti-angiogenic small molecule. Some will also receive SBRT.
Print
Study details
    Advanced Metastatic Pancreatic Cancer

NCT06662006

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

30 July 2026

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.